A cationic peptide, TAT-Cd0, inhibits herpes simplex virus type 1 ocular infection in vivo

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 2, 2013, Pages 1070-1079

  Jose, Gilbert G ^a   Larsen, Inna V ^a   Gauger, Joshua ^a   Carballo, Erica ^a   Stern, Rebecca ^a   Brummel, Rachel ^a   Brandt, Curtis R ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMICROBIAL CATIONIC PEPTIDE; ARTIFICIAL TEAR; METHYLCELLULOSE; PEPTIDE TAT CD 0; PHOSPHATE BUFFERED SALINE; UNCLASSIFIED DRUG; XIPAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEPHARITIS; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; CORNEA STROMA; DISEASE ACTIVITY SCORE; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HERPES SIMPLEX KERATITIS; HERPES SIMPLEX VIRUS 1; IN VIVO STUDY; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION;

ANIMALS; CERCOPITHECUS AETHIOPS; DISEASE MODELS, ANIMAL; DNA, VIRAL; FEMALE; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HUMANS; KERATITIS, HERPETIC; MICE; MICE, INBRED BALB C; PEPTIDES; TREATMENT OUTCOME;

EID: 84875000961     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-10250     Document Type: Article

References (41)

1. Roizman B, Knipe D. Herpes simplex viruses and their replication. In: Knipe DM, Howley PM, eds. Fields Virology. 4th ed. Vol. 2. Philadelphia, PA: Lippincott Williams & Wilkins; 2001:2399-2460.
2. Liesegang TJ, Melton LJ, Daly PJ, Ilstrup DM. Epidemiology of ocular herpes simplex. Incidence in Rochester, Minn, 1950 through 1982. Arch Ophthalmol. 1989;107:1155-1159.
3. Liesegang TJ. Herpes simplex virus epidemiology and ocular importance. Cornea. 2001;20:1-13.
4. Farooq AV, Shukla D. Herpes simplex epithelial and stromal keratitis: an epidemiologic update. Surv Ophthalmol. 2012; 57:448-462.
5. Stuart PM, Summers B, Morris JE, Morrison LA, Leib DA. CD8({thorn}) T cells control corneal disease following ocular infection with herpes simplex virus type 1. J Gen Virol. 2004;85:2055-2063.
6. Suryawanshi A, Mulik S, Sharma S, Reddy PB, Sehrawat S, Rouse BT. Ocular neovascularization caused by herpes simplex virus type 1 infection results from breakdown of binding between vascular endothelial growth factor A and its soluble receptor. J Immunol. 2011;186:3653-3665.
7. Suryawanshi A, Veiga-Parga T, Rajasagi NK, et al. Role of IL-17 and Th17 cells in herpes simplex virus-induced corneal immunopathology. J Immunol. 2011;187:1919-1930.
8. Knickelbein JE, Hendricks RL, Charukamnoetkanok P. Management of herpes simplex virus stromal keratitis: an evidencebased review. Surv Ophthalmol. 2009;54:226-234.
9. Imperia PS, Lazarus HM, Dunkel EC, et al. An in vitro study of ophthalmic antiviral agent toxicity on rabbit corneal epithelium. Antiviral Res. 1988;9:263-272.
10. Lass J, Langston R, Foster C, Pavan-Langston D. Antiviral medications and corneal wound healing. Antiviral Res. 1984; 4:143-157.
11. Fardeau C, Langlois M, Mathys B, et al. Emergence of crossresistant herpes simplex virus following topical drug therapy in rabbit keratitis. Curr Eye Res. 1991;10:151-158.
12. Wilhelmus KR, Gee L, Hauck WW, et al. Herpetic Eye Disease Study. A controlled trial of topical corticosteroids for herpes simplex stromal keratitis. Ophthalmology. 1994;101:1883-1895; discussion 1895-1896.
13. Bultmann H, Brandt CR. Peptides containing membrane transiting motifs inhibit virus entry. J Biol Chem. 2002;277: 36018-36023.
14. Bultmann H, Teuton J, Brandt CR. Addition of a C-terminal cysteine improves the anti-herpes simplex virus activity of a peptide containing the human immunodeficiency virus type 1 TAT protein transduction domain. Antimicrob Agents Chemother. 2007;51:1596-1607.
15. Akkarawongsa R, Cullinan AE, Zinkel A, Clarin J, Brandt CR. Corneal toxicity of cell-penetrating peptides that inhibit herpes simplex virus entry. J Ocul Pharmacol Ther. 2006; 22:279-289.
16. Larsen IV, Brandt CR. A cationic TAT peptide inhibits herpes simplex virus type 1 infection of human corneal epithelial cells. J Ocul Pharmacol Ther. 2010;26:541-547.
17. Brandt CR, Akkarawongsa R, Altmann S, et al. Evaluation of a theta-defensin in a murine model of herpes simplex virus type 1 keratitis. Invest Ophthalmol Vis Sci. 2007;48:5118-5124.
18. Bultmann H, Busse JS, Brandt CR. Modified FGF4 signal peptide inhibits entry of herpes simplex virus type 1. J Virol. 2001;75:2634-2645.
19. Grau DR, Visalli RJ, Brandt CR. Herpes simplex virus stromal keratitis is not titer-dependent and does not correlate with neurovirulence. Invest Ophthalmol Vis Sci. 1989;30:2474-2480.
20. Brandt CR, Spencer B, Imesch P, Garneau M, Deziel R. Evaluation of a peptidomimetic ribonucleotide reductase inhibitor with a murine model of herpes simplex virus type 1 ocular disease. Antimicrob Agents Chemother. 1996;40:1078-1084.
21. Brandt CR, Coakley LM, Grau DR. A murine model of herpes simplex virus-induced ocular disease for antiviral drug testing. J Virol Methods. 1992;36:209-222.
22. Biswas PS, Banerjee K, Kinchington PR, Rouse BT. Involvement of IL-6 in the paracrine production of VEGF in ocular HSV-1 infection. Exp Eye Res. 2006;82:46-54.
23. Fenton RR, Molesworth-Kenyon S, Oakes JE, Lausch RN. Linkage of IL-6 with neutrophil chemoattractant expression in virus-induced ocular inflammation. Invest Ophthalmol Vis Sci. 2002;43:737-743.
24. Kim B, Sarangi PP, Azkur AK, Kaistha SD, Rouse BT. Enhanced viral immunoinflammatory lesions in mice lacking IL-23 respones. Microbes Infect. 2008;10:302-312.
25. Ghate D, Edelhauser HF. Barriers to glaucoma drug delivery. J Glaucoma. 2008;17:147-156.
26. Hughes PM, Olejnik O, Chang-Lin J-E, Wilson CG. Topical and systemic drug delivery to the posterior segments. Adv Drug Deliv Rev. 2005;57:2010-2032.
27. Martin J, Malreddy P, Iwamoto T, et al. NC-1059: a channel-forming peptide that modulates drug delivery across in vitro corneal epithelium. Invest Ophthalmol Vis Sci. 2009;50:3337-3345.
28. Maudgal PC, Clercq ED, Bernaerrs R, et al. Ocular penetration and efficacy of chloroethyldeoxyuridine against herpetic keratouveitis. Invest Ophthalmol Vis Sci. 1986;27:1453-1458.
29. Waltman SR, Patrowicz TC. Effects of hydroxypropyl methylcellulose and polyvinyl alcohol on intraocular penetration of topical fluorescein in man. Invest Ophthalmol Vis Sci. 1970;9: 966-970.
30. Wilson CG. Topical drug delivery in the eye. Exp Eye Res. 2004;78:737-743.
31. Anand BS, Hill JM, Dey S, et al. In vivo antiviral efficacy of a dipeptide acyclovir prodrug, Val-Val-Acyclovir, against HSV-1 epithelial and stromal keratitis in the rabbit eye model. Invest Ophthalmol Vis Sci. 2003;44:2529-2534.
32. Heitz F, Morris MC, Divita G. Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br J Pharmacol. 2009;157:195-206.
33. Liuzzi M, Dezlel R, Moss N, et al. A potent peptidomimetic inhibitor of HSV ribonucleotide reductase with antiviral activity in vivo. Nature. 1994;372:695-698.
34. Meyers-Elliot RH, Chitjian PA, Billups CB. Effects of cyclosporine A on clinical and immunological parameters in herpes simplex keratitis. Invest Ophthalmol Vis Sci. 1987;28:1170-1180.
35. Shuler RK, Dioguardi PK, Henjy C, et al. Scleral permeability of a small, single-stranded oligonucleotide. J Ocul Pharmacol Ther. 2004;20:159-168.
36. Yasin B, Wang W, Pang M, et al. Theta defensins protect cells from infection by herpes simplex virus by inhibiting viral adhesion and entry. J Virol. 2004;78:5147-5156.
37. Trabi M, Schirra H, Craik D. Three-dimensional structure of RTD-1, a cyclic antimicrobial defensin from Rhesus macaque leukocytes. Biochemistry. 2001;40:4211-4221.
38. Cole A, Hong T, Boo L, et al. Retrocyclin: a primate peptide that protects cells from infection by T-and M-tropic strains of HIV-1. Proc Natl Acad Sci U S A. 2002;99:1813-1818.
39. Daher K, Selsted M, Lehrer R. Direct inactivation of viruses by human granulocyte defensins. J Virol. 1986;60:1068-1074.
40. Leikina E, Delanoe-Ayari H, Melikov K, et al. Carbohydratebinding molecules inhibit viral fusion and entry by crosslinking membrane glycoproteins. Nat Immunol. 2005;6:995-1001.
41. Gallo S, Wang W, Rawat S, et al. Theta-defensins prevent HIV-1 Env-mediated fusion by binding gp41 and blocking 6-helix bundle formation. J Biol Chem. 2006;281:18787-18792.